Ocugen R&D Spending Growth & History (OCGN)
Ocugen's r&d spending was $39.8M for fiscal 2025.
View full Ocugen company overviewOcugen annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $39.8M | $7.6M | +23.73% |
| 2024 | 2024-12-31 | $32.1M | −$7.4M | −18.82% |
| 2023 | 2023-12-31 | $39.6M | −$16.6M | −29.53% |
| 2022 | 2022-12-31 | $56.2M | $21.1M | +59.96% |
| 2021 | 2021-12-31 | $35.1M | $28.8M | +452.53% |
| 2020 | 2020-12-31 | $6.4M | −$1.7M | −21.42% |
| 2019 | 2019-12-31 | $8.1M | −$2.2M | −21.66% |
| 2018 | 2018-12-31 | $10.3M | −$5.2M | −33.69% |
| 2017 | 2017-12-31 | $15.6M | −$6.0M | −27.86% |
| 2016 | 2016-12-31 | $21.6M | −$1.7M | −7.17% |
| 2015 | 2015-12-31 | $23.2M | −$2.8M | −10.73% |
| 2014 | 2014-12-31 | $26.0M | — | — |
Ocugen quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.7M | $2.3M | +27.23% |
| Q1 2026 | 2026-03-31 | $11.3M | $1.7M | +18.11% |
| Q4 2025 | 2025-12-31 | $10.7M | $2.4M | +28.71% |
| Q3 2025 | 2025-09-30 | $11.1M | $3.0M | +37.51% |
| Q2 2025 | 2025-06-30 | $8.4M | −$500,000 | −5.62% |
| Q1 2025 | 2025-03-31 | $9.5M | $2.7M | +39.60% |
| Q4 2024 | 2024-12-31 | $8.3M | $511,000 | +6.57% |
| Q3 2024 | 2024-09-30 | $8.1M | $1.1M | +15.04% |
| Q2 2024 | 2024-06-30 | $8.9M | −$5.7M | −38.92% |
| Q1 2024 | 2024-03-31 | $6.8M | −$3.3M | −32.89% |
| Q4 2023 | 2023-12-31 | $7.8M | −$9.4M | −54.84% |
| Q3 2023 | 2023-09-30 | $7.0M | −$10.9M | −60.71% |
| Q2 2023 | 2023-06-30 | $14.6M | $3.0M | +25.62% |
| Q1 2023 | 2023-03-31 | $10.2M | $779,000 | +8.29% |
| Q4 2022 | 2022-12-31 | $17.2M | $10.1M | +142.57% |
| Q3 2022 | 2022-09-30 | $17.9M | $11.7M | +185.58% |
| Q2 2022 | 2022-06-30 | $11.6M | −$7.3M | −38.46% |
| Q1 2022 | 2022-03-31 | $9.4M | $6.5M | +227.05% |
| Q4 2021 | 2021-12-31 | $7.1M | $5.5M | +345.55% |
| Q3 2021 | 2021-09-30 | $6.3M | $4.8M | +324.97% |
| Q2 2021 | 2021-06-30 | $18.9M | $17.2M | +1056.63% |
| Q1 2021 | 2021-03-31 | $2.9M | $1.2M | +73.85% |
| Q4 2020 | 2020-12-31 | $1.6M | −$153,470 | −8.78% |
| Q3 2020 | 2020-09-30 | $1.5M | $172,539 | +13.22% |
| Q2 2020 | 2020-06-30 | $1.6M | $389,953 | +31.45% |
| Q1 2020 | 2020-03-31 | $1.7M | −$2.1M | −56.45% |
| Q4 2019 | 2019-12-31 | $1.7M | $731,359 | +71.98% |
| Q3 2019 | 2019-09-30 | $1.3M | −$255,825 | −16.39% |
| Q2 2019 | 2019-06-30 | $1.2M | −$3.2M | −72.18% |
| Q1 2019 | 2019-03-31 | $3.8M | $507,022 | +15.43% |
| Q4 2018 | 2018-12-31 | $1.0M | −$2.3M | −69.81% |
| Q3 2018 | 2018-09-30 | $1.6M | −$1.9M | −55.24% |
| Q2 2018 | 2018-06-30 | $4.5M | $250,000 | +5.94% |
| Q1 2018 | 2018-03-31 | $3.3M | −$1.2M | −27.04% |
| Q4 2017 | 2017-12-31 | $3.4M | −$2.0M | −36.69% |
| Q3 2017 | 2017-09-30 | $3.5M | −$1.4M | −28.52% |
| Q2 2017 | 2017-06-30 | $4.2M | −$1.6M | −27.37% |
| Q1 2017 | 2017-03-31 | $4.5M | −$1.1M | −19.37% |
| Q4 2016 | 2016-12-31 | $5.3M | −$456,000 | −7.90% |
| Q3 2016 | 2016-09-30 | $4.9M | −$968,000 | −16.55% |
| Q2 2016 | 2016-06-30 | $5.8M | −$64,000 | −1.09% |
| Q1 2016 | 2016-03-31 | $5.6M | −$178,000 | −3.09% |
| Q4 2015 | 2015-12-31 | $5.8M | $1.0M | +21.36% |
| Q3 2015 | 2015-09-30 | $5.8M | −$7.4M | −55.82% |
| Q2 2015 | 2015-06-30 | $5.9M | $1.2M | +25.47% |
| Q1 2015 | 2015-03-31 | $5.8M | $2.4M | +70.84% |
| Q4 2014 | 2014-12-31 | $4.8M | — | — |
| Q3 2014 | 2014-09-30 | $13.2M | — | — |
| Q2 2014 | 2014-06-30 | $4.7M | — | — |
| Q1 2014 | 2014-03-31 | $3.4M | — | — |
Ocugen r&d spending trends
Over the last five fiscal years, Ocugen's r&d spending increased from $6.4M to $39.8M, a change of $33.4M. The latest reported quarter, Q2 2026, shows $10.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocugen source filings ↗